Cyanocobalamin

Introduction Overview

Generic Name

Cyanocobalamin

Brand Name

B-12, Vitafusion B-12 Gummies, Vitamin B-12, Vitamin B-12 Time Release

Dosage Form

oral liquid, oral tablet, chewable tablet, disintegrating tablet, extended-release tablet, sublingual liquid, sublingual lozenge, sublingual tablet

Drug Class

Vitamins

Pharmacokinetics

Absorption:
Cyanocobalamin, a synthetic form of vitamin B12, is absorbed in the gastrointestinal tract primarily through an intrinsic factor-mediated active transport mechanism located in the ileum. When administered orally, cyanocobalamin is released from dietary proteins or supplements and binds to intrinsic factor secreted by gastric parietal cells. This complex facilitates absorption in the terminal ileum via receptor-mediated endocytosis. A small percentage of cyanocobalamin can also be absorbed by passive diffusion along the entire intestine, which becomes clinically significant with high oral doses. Factors impairing intrinsic factor production, such as pernicious anemia or gastric surgery, markedly reduce active absorption, necessitating alternative administration routes or higher oral doses that rely on passive absorption.

Distribution:
Once absorbed, cyanocobalamin enters systemic circulation bound to transcobalamin II, a plasma carrier responsible for delivering vitamin B12 to cells and tissues. The vitamin is widely distributed throughout the body, accumulating primarily in the liver, which serves as the main storage site. The liver stores sufficient quantities to supply the body's requirements for several years. Cyanocobalamin also distributes to other tissues such as the bone marrow, kidneys, and brain. Cellular uptake involves receptor-mediated endocytosis of the cyanocobalamin-transcobalamin complex. The vitamin's extensive tissue distribution underscores its vital role in multiple physiological functions, including erythropoiesis and neurological maintenance.

Metabolism:
Cyanocobalamin undergoes enzymatic conversion intracellularly to its active coenzyme forms: methylcobalamin and adenosylcobalamin. These coenzymes participate in critical biochemical reactions. Methylcobalamin serves as a cofactor for methionine synthase, which catalyzes the remethylation of homocysteine to methionine, a key step in DNA synthesis. Adenosylcobalamin functions as a cofactor for methylmalonyl-CoA mutase, which is crucial for the metabolism of certain amino acids and fatty acids. Cyanide, released from cyanocobalamin, is detoxified by conversion to thiocyanate in the liver. The metabolic conversion is essential for the biological activity of vitamin B12; deficiencies impair DNA synthesis and myelin production.

Elimination:
The elimination of cyanocobalamin and its metabolites occurs primarily via biliary excretion into the feces, followed by enterohepatic circulation and subsequent reabsorption. A small fraction is excreted unchanged in the urine, especially when plasma levels exceed the renal threshold. Renal function therefore influences urinary excretion. The half-life of vitamin B12 in plasma ranges from days to weeks, reflecting slow turnover and retention in tissue stores. Continuous recycling through enterohepatic circulation contributes to the maintenance of vitamin B12 homeostasis under physiological conditions. In cases of deficiency, the stores deplete slowly, necessitating prolonged supplementation to restore adequate levels.

Dosage Forms

Available Dosage Forms:
Cyanocobalamin is available in multiple oral formulations designed to accommodate patient preferences and optimize absorption. These include:
- Oral liquid: 1000 mcg per 15 mL
- Oral tablets: 50 mcg, 100 mcg, 250 mcg, 500 mcg, 1000 mcg, 2500 mcg
- Oral chewable tablets: 500 mcg
- Oral disintegrating tablets: 5000 mcg
- Oral extended-release tablets: 1000 mcg, 5000 mcg
- Sublingual liquids: 3000 mcg/mL
- Sublingual lozenges: 1000 mcg, 6000 mcg
- Sublingual tablets: 500 mcg, 1000 mcg, 2500 mcg, 5000 mcg

Dosages for Adults and Adolescents:
For pernicious anemia, intramuscular or deep subcutaneous administration of 100 mcg daily for 6-7 days is typical, followed by progressive tapering to maintenance dosing of 100-1000 mcg monthly, often lifelong. For nutritional vitamin B12 deficiency, oral dosing ranges broadly from 25 to 2000 mcg daily depending on severity. The Schilling test uses a flushing dose of 1000 mcg intramuscularly. Dosing must be individualized based on clinical response and laboratory monitoring.

Specific Patient Populations:
Pediatric dosing for nutritional deficiency ranges from 0.5 to 3 mcg daily. In patients with malabsorption syndromes or pernicious anemia, parenteral vitamin B12 administration is preferred due to impaired absorption of oral forms. Extended-release and sublingual formulations provide alternative routes aiming to enhance compliance and bioavailability for patients intolerant of injections or with mild absorption deficits. Clinical guidance emphasizes consultation with healthcare providers to tailor doses for pregnancy, lactation, and comorbid conditions requiring blood thinners or other interacting medications.

Mechanism Of Action

Cyanocobalamin functions as a synthetic precursor of vitamin B12, an essential water-soluble vitamin involved in DNA synthesis, methylation reactions, and neurological function. Upon administration, cyanocobalamin is converted enzymatically in the body to its active coenzyme forms: methylcobalamin and adenosylcobalamin.

Methylcobalamin acts as a cofactor for methionine synthase, catalyzing the methylation of homocysteine to methionine. This reaction is critical for the generation of S-adenosylmethionine (SAM), a universal methyl donor involved in numerous methylation processes including DNA, RNA, protein, and lipid methylation. This molecular mechanism underpins cyanocobalamin's role in nucleic acid synthesis and cellular replication, particularly evident in hematopoietic and neurological tissues.

Adenosylcobalamin is a coenzyme for methylmalonyl-CoA mutase, facilitating the isomerization of methylmalonyl-CoA to succinyl-CoA, a key step in energy production through the citric acid cycle and in the catabolism of fatty acids and certain amino acids. Deficiency disrupts this pathway, leading to accumulation of methylmalonic acid and consequent neurological dysfunction.

Clinically, cyanocobalamin's molecular action restores normal hematopoiesis and prevents neurological damage associated with vitamin B12 deficiency. Compared to hydroxocobalamin, another vitamin B12 form with similar efficacy, cyanocobalamin contains a cyanide moiety, which is rapidly removed and detoxified, and is widely used for its stability and cost-effectiveness. Numerous clinical trials have demonstrated its effectiveness in reversing megaloblastic anemia, neuropathy, and cognitive symptoms linked to B12 deficiency.

Pharmacological Actions

Essential for DNA synthesis and cellular replication via methylation processes.
Coenzyme activity in methionine synthase-catalyzed methylation of homocysteine to methionine.
Support of hematopoietic function by facilitating red blood cell maturation.
Acts as a cofactor for methylmalonyl-CoA mutase in energy metabolism.
Maintains nervous system health through myelin synthesis and repair.
Reduces elevated homocysteine levels, a cardiovascular risk factor.
Improves cognitive function and neurological symptoms related to B12 deficiency.
Contributes to the metabolism of fatty acids and certain amino acids.
Facilitates cellular methylation reactions critical to epigenetic regulation.
Supports immune system function by influencing lymphocyte proliferation.
Proven efficacy in treating pernicious anemia and other megaloblastic anemias.
Works synergistically with folic acid to optimize hematological and neurological outcomes.
Beneficial in reducing symptoms of B12 nutritional deficiency.
Used in diagnostic Schilling test to assess vitamin B12 absorption.
Available in various formulations for flexible routes of administration.

Therapeutic Or Clinical Uses

Treatment and prevention of vitamin B12 deficiency states including pernicious anemia.
Management of nutritional vitamin B12 deficiency due to inadequate dietary intake or absorption.
Adjunctive treatment in malabsorption syndromes affecting vitamin B12 uptake.
Used in the Schilling test to evaluate intrinsic factor-related absorption defects.
Potential use to lower elevated homocysteine levels associated with cardiovascular risk.
Supportive therapy in neuropathies caused by B12 deficiency, including peripheral neuropathy.
Treatment of megaloblastic anemia due to defective DNA synthesis.
Used to restore normal hematologic parameters during chronic B12 deficiency.
Investigated for cognitive enhancement and Alzheimer's disease symptom management (though evidence is limited).
Employed in alternative medicine for canker sores to aid mucosal healing.
Support for maintaining bone health in patients with low vitamin B12.
Utilized in cases of sleep disorders potentially linked to B12 deficiency (research inconclusive).
Prevention of neurological complications in individuals with gastric or intestinal surgeries.
Used in patients with chronic alcoholism experiencing impaired B12 absorption.
Non-prescription use as a vitamin supplement to maintain adequate B12 levels.

Side Or Adverse Effects

Allergic reactions including hives, swelling of the face, lips, tongue, or throat, and difficulty breathing.
Mild gastrointestinal symptoms such as nausea, diarrhea, or upset stomach.
Local injection site reactions in parenteral administration (pain, swelling).
Rare cases of anaphylaxis have been reported following cyanocobalamin injections.
Skin rashes or itching may occasionally occur.
Headache, dizziness, or feeling lightheaded reported in some patients.
Transient polycythemia due to rapid hematologic response.
Hypokalemia during intensive therapy due to improved erythropoiesis.
Rare thrombocytosis or leukocytosis during treatment.
Renal impairment may increase serum cobalamin levels leading to laboratory anomalies.
Possible exacerbation of pre-existing hypokalemia in susceptible individuals.
Injection-related complications such as pain, infection, or swelling when administered intramuscularly.
Rare cardiovascular reactions including chest pain reported anecdotally.
Transient flushing or a sensation of warmth after administration.
No significant teratogenic effects reported; however, caution is advised during pregnancy.

Precautions

Do not use if allergic to vitamin B12, cobalamin, or cobalt.
Use cautiously in patients with malabsorption syndromes; higher or parenteral dosing may be necessary.
Monitor renal function as impaired clearance may affect serum levels.
Inform healthcare providers if using anticoagulants such as warfarin due to possible interaction.
Avoid concurrent use of multiple cyanocobalamin forms to prevent overdose.
Refrigerate oral liquid formulations after opening to preserve potency.
Measure liquid doses accurately using supplied measuring devices, not household spoons.
Use with caution in pregnant or breastfeeding women; consult healthcare provider.
Advise patients on proper administration techniques for chewable, disintegrating, and sublingual tablets.
Patients with cancer should seek medical advice before use, as B12 may affect tumor growth.
Avoid alcohol consumption as heavy use may impair B12 absorption and efficacy.
Disclose all concomitant therapies to healthcare providers to avoid adverse interactions.
Regularly monitor vitamin B12 levels during long-term therapy to adjust dosing.
Carefully follow instructions regarding administration with or without food to optimize absorption.
Inform surgeons prior to operations to prevent interference with surgical outcomes.

Warnings

Seek emergency medical attention if signs of allergic reaction occur.
Do not exceed recommended doses to prevent toxicity or adverse effects.
Long-term therapy is usually required for pernicious anemia; abrupt discontinuation may cause relapse.
Cyanocobalamin can affect laboratory test results, inform laboratory personnel accordingly.
Use caution in patients with hypokalemia; correction of potassium levels may be needed during treatment.
Not effective in treating anemia not caused by vitamin B12 deficiency; misdiagnosis may delay proper treatment.
Not recommended for treatment of Alzheimer’s disease or cognitive decline outside of deficiency states.
Ensure differentiated diagnosis to exclude folic acid deficiency, as isolated folate therapy can worsen neurological symptoms.
Avoid concurrent use with high-dose vitamin C supplements without medical advice as it may reduce B12 bioavailability.
Avoid use in children without specific medical recommendation due to potential dosing risks.
Overdose symptoms require immediate medical intervention.
Pregnant or breastfeeding women must use only under medical supervision.
Proper storage conditions must be maintained to prevent drug degradation.
Monitor for any neurological symptom progression despite therapy.
Patients should report any unusual symptoms during treatment promptly.

Contraindication

Known allergy or hypersensitivity to cyanocobalamin, vitamin B12, cobalamins, or cobalt compounds.
Patients with Leber's disease (hereditary optic nerve atrophy) as B12 may exacerbate damage.
Use contraindicated without medical supervision in infants or children without established deficiency.
Avoid use in patients with untreated folate deficiency anemia as sole treatment.
Not contraindicated but caution advised in patients with malignancy without physician oversight.
Do not use concurrently with incompatible medications without professional consultation.
Contraindicated in cases with severe hypersensitivity reactions in past B12 therapy.
Avoid if previous adverse reactions to injectable formulations occurred.
Not recommended for cyanide poisoning treatment; hydroxocobalamin preferred.
Avoid use in patients with known cobalt toxicity.
Use contraindicated in patients with known metabolic disorders affecting vitamin B12 processing.
Contraindicated without proper diagnosis of deficiency to avoid masking other hematologic diseases.
Not recommended as sole therapy in complex anemias without additional evaluation.
Avoid over-the-counter use in complex neurological disorders without specialist input.
Contraindicated in combined cobalamin and folate deficiency without medical management.
Avoid in persons with vitamin B12 absorption studies unless medically indicated.

Drug Interactions

Vitamin C supplements may reduce absorption and bioavailability of cyanocobalamin when taken concurrently.
Folic acid supplementation can mask hematologic symptoms of B12 deficiency, delaying diagnosis.
Potassium supplements may interact, requiring monitoring of electrolyte balance during therapy.
Metformin, used in type 2 diabetes, impairs B12 absorption leading to potential deficiency.
Histamine H2-receptor antagonists such as cimetidine decrease gastric acid, impairing B12 absorption.
Proton pump inhibitors including omeprazole, lansoprazole, and esomeprazole reduce stomach acid and may lower B12 absorption.
Antibiotics that alter gut flora can modulate B12 availability indirectly.
Chloramphenicol may antagonize the hematologic effects of cyanocobalamin.
Heavy alcohol use reduces intestinal absorption and increases B12 requirements.
Chronic use of colchicine may decrease B12 absorption and serum levels.
Nitrous oxide anesthesia oxidizes B12 and can precipitate deficiency in susceptible patients.
Clozapine and other antipsychotics can potentially interact affecting B12 metabolism.
Long-term use of metformin strongly correlated with decreased vitamin B12 absorption; monitoring advised.
Concurrent use with sulfasalazine may impair B12 absorption.
Certain anticonvulsants may increase the metabolism of vitamin B12.

Preparations Of The Drug

Oral liquid formulations, typically at 1000 mcg per 15 mL doses, designed for ease of swallowing and accurate dosing.
Immediate-release oral tablets available in several strengths ranging from 50 mcg to 2500 mcg to tailor therapy.
Chewable oral tablets at 500 mcg for patients requiring altered administration due to swallowing difficulties.
Disintegrating oral tablets, notably at 5000 mcg, providing rapid dissolution and absorption in the oral cavity.
Extended-release oral tablets formulated to provide sustained vitamin B12 levels over extended periods.
Sublingual liquids, commonly at 3000 mcg/mL, allowing direct mucosal absorption bypassing gastrointestinal barriers.
Sublingual lozenges at doses such as 1000 mcg and 6000 mcg to maximize mucosal uptake with convenient administration.
Sublingual tablets available in multiple doses including 500 mcg to 5000 mcg to provide flexible sublingual therapy.
Parenteral preparations (not detailed here) including intramuscular and subcutaneous injections for rapid or refractory cases.
Nasal sprays and gels (other formulations) designed for alternative routes, particularly in malabsorption states.
Vitamin B12 combination supplements that may include folic acid or other B-complex vitamins for comprehensive support.
Unit-dose packaging for extended-release and sublingual formulations to ensure accurate daily dosing and compliance.
Suppositories and topical forms in development or limited availability for specific clinical scenarios.
Supplement formulations including gummies aimed at improving patient compliance in preventative care.
Stability preserved by protection from light, moisture, and heat to maintain efficacy during shelf life.